GeneDx Holdings Corp. (WGS) - Total Liabilities
Based on the latest financial reports, GeneDx Holdings Corp. (WGS) has total liabilities worth $252.18 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GeneDx Holdings Corp. - Total Liabilities Trend (2020–2025)
This chart illustrates how GeneDx Holdings Corp.'s total liabilities have evolved over time, based on quarterly financial data. See GeneDx Holdings Corp. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
GeneDx Holdings Corp. Competitors by Total Liabilities
The table below lists competitors of GeneDx Holdings Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Jinqiao Export Processing Zone Development Co Ltd A
SHG:600639
|
China | CN¥28.17 Billion |
|
United States Steel Corp
BA:X
|
Argentina | AR$8.75 Billion |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥136.00 Million |
|
Sixt SE
XETRA:SIX3
|
Germany | €5.56 Billion |
|
Beijing Sanju Environmental
SHE:300072
|
China | CN¥2.51 Billion |
|
Ramsay Generale De Sante
PA:GDS
|
France | €5.41 Billion |
|
Ami Organics Limited
NSE:AMIORG
|
India | Rs2.29 Billion |
|
Instalco Intressenter AB
ST:INSTAL
|
Sweden | Skr6.87 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down GeneDx Holdings Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GeneDx Holdings Corp. market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeneDx Holdings Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeneDx Holdings Corp. (2020–2025)
The table below shows the annual total liabilities of GeneDx Holdings Corp. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $262.01 Million | +50.46% |
| 2024-12-31 | $174.13 Million | -8.71% |
| 2023-12-31 | $190.74 Million | -34.58% |
| 2022-12-31 | $291.56 Million | +75.65% |
| 2021-12-31 | $165.99 Million | -32.87% |
| 2020-12-31 | $247.25 Million | -- |
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and can… Read more